Published Studies

Always you, always new.
Peer-Reviewed Evidence

Published Clinical Studies

BEMER Physical Vascular Therapy has been the subject of peer-reviewed clinical research published in indexed medical journals. The three studies below represent the published literature from the foundational research period — independently reviewed, placebo-controlled where applicable, and available in full via the cited journals.

These studies form part of a broader clinical evidence base accumulated across 25 years of use in over 40 countries. The full body of research — spanning 15 medical specialties and more than 3,000 patients in observational and multi-centre settings — is summarised in the Research by Condition index.

Study 1 — Randomised Controlled Trial

MS-Related Fatigue

Piatkowski J, Kern S, Ziemssen T. Effect of BEMER Physical Vascular Therapy on Fatigue of Patients with Multiple Sclerosis: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial. Journal of Alternative and Complementary Medicine. 2009;15(5):507–511. DOI: 10.1089/acm.2008.0501

Study type

Monocenter, patient- and rater-blinded, placebo-controlled randomised trial

Ethics

International Ethical Committee, Freiburg (EC 02/TS/06); Declaration of Helsinki

Institution

Department of Neurology, University of Dresden

Population

41 enrolled, 37 with complete data (19 verum, 18 placebo) — RRMS with significant fatigue

Duration

12 weeks

Protocol

BEMER 3000 mat, 8 minutes twice daily at home; identical sham device for the placebo group; compliance monitored by diary

Measure
BEMER
Placebo
MFIS total at 12 weeksp=0.024
26.84
36.67
Fatigue Severity Scalep=0.016
3.5
4.7

Both physical and cognitive dimensions of fatigue improved significantly; the psychological/psychosocial dimension showed no significant group difference. No adverse events were recorded.

“We were able to demonstrate a beneficial effect of BEMER intervention on MS fatigue.” — study authors

The only published RCT of BEMER for any neurological condition — conducted at a university neurology department, reaching statistical significance on both primary and secondary fatigue measures.

Study 2 — Randomised Controlled Trial

Subjective Tinnitus

Szilágyi I. BEMER Physical Vascular Therapy in the Treatment of Subjective Tinnitus. Otorhinologica Hungaria. 2010;56(4):251–260.

Study type

Randomised, double-blind, placebo-controlled clinical trial

Institution

ENT Department, Dr. Bugyi István Hospital, Szentes, Hungary

Population

214 patients — 108 BEMER, 106 placebo; idiopathic, noise-induced, and presbycusis-associated tinnitus

Period

July 2009 – June 2010

Protocol

8 consecutive days — 8 min whole-body mat + 20 min intensive applicator on the temporal region; both groups on standard pharmacotherapy (Pentoxifylline IV + Piracetam)

Measure
BEMER
Placebo
Tinnitus stopped
22.2%
8.5%
Tinnitus improved
47.3%
36.8%
Total positive response
69.5%
45.3%
Unchanged
30.5%
53.8%
Worsened
0%
0.94%

χ² test, p=0.001. BEMER combined with standard pharmacotherapy significantly outperformed pharmacotherapy alone for subjective tinnitus across all patient subgroups, with the best results in lower-severity tinnitus. No harmful side effects occurred in either group.

The largest BEMER RCT in the published literature — 214 patients, double-blind design, a statistically highly significant result across a well-characterised patient population.

Study 3 — Statutory Market Monitoring (Peer-Reviewed)

Quality of Life, Pain and Sleep

Bohn W, Hess L, Burger R. Results of a Market Monitoring Study of the BEMER Physical Vascular Therapy. Journal of Complementary and Integrative Medicine. 2013;10(Suppl):S5–S12. DOI: 10.1515/jcim-2013-0037

Study type

Statutory market monitoring of a CE-certified Class IIa medical device; peer-reviewed publication

Population

658 valid patient questionnaires across multiple diagnoses

Period

April 2011 – March 2013

Duration

6 weeks

Outcome measures

Jenkins Sleep Scale, NRS/VAS pain assessment, SF-12 Quality of Life questionnaire

Statistically significant improvements in sleep quality, pain, and quality of life — consistent across all underlying disease groups in the monitoring period.

A peer-reviewed publication based on statutory device monitoring — the regulatory evidence required for a CE-certified medical device — validating BEMER's effects across a broad mixed-diagnosis population using three established, validated outcome instruments simultaneously.

The Evidence Context

These three publications represent the indexed, peer-reviewed tier of BEMER's clinical evidence base. They sit within a much larger body of observational and multi-centre clinical data:

AFB Multi-Centre Study (1999–2002)

1,116 patients across 220 medical facilities in Germany, Austria, and Switzerland — the largest single observational dataset

Schönfeld General Practice Study (1999–2000)

201 patients, 87.6% positive outcomes across acute and chronic conditions

Klopp microcirculation research (2008)

Controlled studies demonstrating measurable microcirculatory improvements in diabetic polyneuropathy within 8–10 days

The full spectrum of conditions studied — with evidence levels, sample sizes, and outcome percentages — is indexed in the Research by Condition section.

Get Well Now is an independent BEMER SA agent and does not conduct or fund research. The studies referenced here reflect published, publicly available evidence. Always discuss BEMER therapy with your healthcare provider in the context of your specific health conditions.